Apellis Pharmaceuticals Inc (NASDAQ:APLS) was the target of some unusual options trading on Monday. Stock traders acquired 2,653 call options on the stock. This represents an increase of approximately 2,379% compared to the average volume of 107 call options.

In related news, CEO Cedric Francois sold 5,000 shares of the business’s stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $27.82, for a total value of $139,100.00. Also, COO Pascal Deschatelets sold 42,460 shares of the stock in a transaction dated Tuesday, September 24th. The shares were sold at an average price of $24.82, for a total value of $1,053,857.20. In the last 90 days, insiders sold 57,460 shares of company stock worth $1,464,957. Company insiders own 10.60% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of APLS. Jennison Associates LLC increased its holdings in shares of Apellis Pharmaceuticals by 57.2% in the second quarter. Jennison Associates LLC now owns 923,244 shares of the company’s stock valued at $23,395,000 after buying an additional 335,863 shares in the last quarter. Eversept Partners LP raised its holdings in Apellis Pharmaceuticals by 12.4% during the 2nd quarter. Eversept Partners LP now owns 117,309 shares of the company’s stock worth $2,973,000 after buying an additional 12,960 shares during the period. Athanor Capital LP purchased a new stake in Apellis Pharmaceuticals during the second quarter valued at about $385,000. SG Americas Securities LLC purchased a new stake in Apellis Pharmaceuticals during the third quarter valued at about $1,585,000. Finally, Strs Ohio acquired a new position in shares of Apellis Pharmaceuticals in the third quarter worth about $814,000. 61.68% of the stock is owned by institutional investors.

NASDAQ:APLS opened at $26.86 on Tuesday. Apellis Pharmaceuticals has a 1 year low of $12.16 and a 1 year high of $33.18. The business has a fifty day moving average of $28.27 and a 200-day moving average of $26.08. The company has a debt-to-equity ratio of 1.09, a current ratio of 10.12 and a quick ratio of 10.12.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.09). Analysts forecast that Apellis Pharmaceuticals will post -4.09 earnings per share for the current year.

Several equities research analysts have weighed in on the company. Zacks Investment Research raised Apellis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, November 25th. Credit Suisse Group initiated coverage on shares of Apellis Pharmaceuticals in a research report on Tuesday, November 5th. They set a “neutral” rating and a $33.00 price target for the company. ValuEngine cut shares of Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Wedbush initiated coverage on shares of Apellis Pharmaceuticals in a research report on Wednesday, November 27th. They issued an “underperform” rating and a $23.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $54.00 target price (up previously from $50.00) on shares of Apellis Pharmaceuticals in a research report on Monday, November 25th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. Apellis Pharmaceuticals presently has an average rating of “Hold” and an average target price of $41.78.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.

Featured Story: Short Selling

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.